Neocartilage Implant to Treat Cartilage Lesions of the Knee

Sponsor
ISTO Technologies, Inc. (Industry)
Overall Status
Terminated
CT.gov ID
NCT01400607
Collaborator
(none)
14
9
2
110.1
1.6
0

Study Details

Study Description

Brief Summary

ISTO Technologies, Inc. is proposing a clinical study with 225 subjects, to establish the safety and efficacy of the Neocartilage Implant for the treatment of ICRS Grade 3 and 4 articular cartilage lesions of the knee compared to microfracture treatment.

Condition or Disease Intervention/Treatment Phase
  • Biological: Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)
  • Other: Microfracture
Phase 3

Detailed Description

In the United States alone, more than 500,000 cartilage lesions per year require some treatment to reduce pain, restore joint mobility, and prevent further damage caused by the progression of osteoarthritis. The lack of effective cartilage repair approaches or products for restoration of defective articular cartilage to its native, hyaline morphology only continues to exacerbate the incidence of osteoarthritis as these initial defects enlarge and degrade over a 10 to 20 year period. The repair of cartilage, especially in the knee, remains a formidable clinical challenge. Regenerative medicine approaches to cartilage repair have only begun to be explored as possible options and there is a clear trend toward biological solutions for the repair and regeneration of damaged or diseased articular cartilage. The study was designed to compare how well the Neocartilage Implant works against the microfracture therapy, a widely used and accepted cartilage repair therapy. Data to be collected include Pain and Function in Daily Living scores, symptoms, Function in Sports and Recreation, and Knee Related Quality of Life. Additionally, MRI and X-rays will be collected to evaluate the cartilage repair progress. These assessments will be used through the five years of post-operative follow-up.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Controlled Trial to Evaluate the Efficacy of a Neocartilage Implant in the Management of ICRS Grade 3 to 4 Articular Cartilage Lesions of the Knee
Study Start Date :
Jul 1, 2011
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Sep 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Neocartilage Implant

Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.

Biological: Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)
The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
Other Names:
  • RevaFlex
  • Other: Microfracture

    Standard of care cartilage repair technique.

    Other: Microfracture
    Marrow stimulation using the microfracture technique; performed arthroscopically
    Other Names:
  • marrow stimulation
  • Outcome Measures

    Primary Outcome Measures

    1. Knee Injury and Osteoarthritis Outcomes Scores (KOOS) [36 months]

      Knee Injury and Osteoarthritis Outcomes Scores (KOOS) Pain and Function in Daily Living (ADL) subscales.

    Secondary Outcome Measures

    1. IKDC Knee Examination [Baseline, 6 week, 6, 12, 18, 24 months and annually through 5 years]

    2. Subject reported questionnaires [Baseline, 6 week, 6, 12, 18, 24 months and annually through 5 years]

      Various questionnaires are required to be completed by the subject before and after treatment throughout the study.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Generally, the following inclusion criteria must be met, however, this is not a complete list.

    • Male or Female between the ages of 18 and 60

    • (1) or (2) articular cartilage lesions of the distal femur ranging in no more than 5 cm2 each

    • Ipsilateral knee compartment has intact menisci (or meniscectomized remnant with > 5mm wide rim) and stable ligaments in the affected knee

    • 3 months out from initiation of conservative non-surgical management (e.g.hyaluronic acid injection, activity modification) or previous minimal surgical intervention (e.g., arthroscopic lavage, debridement) or 12 months out from marrow stimulation for this condition

    Exclusion Criteria:

    Generally, if a potential participant meets any of the following criterions, they will not be eligible for this study. Additionally, more criteria will be evaluated to confirm eligibility as this list is not a complete list of criteria.

    • Osteoarthritis

    • Rheumatoid arthritis

    • History of septic or reactive arthritis

    • Gout or a history of gout or pseudo-gout in the affected knee

    • Osteochondritis dissecans or osteochondral lesions of the knee with bone loss > 6mm deep

    • Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface)

    • Associated damage to the underlying subchondral bone requiring an osteochondral graft

    • Is pregnant or breast-feeding

    • Has a BMI > 35 (kg/m2)

    • Has prior total meniscectomy of either knee

    • Has received, within the past three months, intra-articular hyaluronic acid therapy, or steroid therapy

    • Has more than two clinically relevant chondral lesion(s) on the index knee

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kerlan Jobe Orthopaedic Clinic Los Angeles California United States 90045
    2 Santa Monica Orthopaedic & Sports Medicine Group Santa Monica California United States 90404
    3 Rush University Medical Center Chicago Illinois United States 60612
    4 Hospital for Special Surgery -Sports Medicine and Shoulder Service New York New York United States 10021
    5 Insall Scott Kelly Institute for Orthopaedics & Sports Medicine New York New York United States 10065
    6 Cleveland Clinic Cleveland Ohio United States 44195
    7 The Ohio State University Sports Medicine Center Columbus Ohio United States 43221
    8 The Hawkins Foundation Greenville South Carolina United States 29615
    9 The Methodist Hospital Research Institute Houston Texas United States 77030

    Sponsors and Collaborators

    • ISTO Technologies, Inc.

    Investigators

    • Study Director: Michaela Purcell, ISTO Technologies, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ISTO Technologies, Inc.
    ClinicalTrials.gov Identifier:
    NCT01400607
    Other Study ID Numbers:
    • ISTO NEO-01-09-01
    First Posted:
    Jul 22, 2011
    Last Update Posted:
    Aug 31, 2017
    Last Verified:
    Sep 1, 2016

    Study Results

    No Results Posted as of Aug 31, 2017